FDA Adverse Event Death Summary report: N

PIPELINE

MDR report key: 13445907 · Received February 3, 2022

Report

Report Number
2029214-2022-00151
Event Type
Death
Date Received
February 3, 2022
Date of Event
November 2, 2020
Report Date
February 3, 2022
Manufacturer
MICRO THERAPEUTICS, INC. DBA EV3
Product Code
OUT
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

REPORTED PATIENT AGE (53 YEARS) IS REPRESENTATIVE OF THE MEAN AGE OF ALL PATIENTS INCLUDED IN THE STUDY. REPORTED PATIENT SEX (FEMALE) IS REPRESENTATIVE OF THE MAJORITY OF PATIENTS INCLUDED IN THE STUDY. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 0

LUO, B., KANG, H., ZHANG, H., LI, T., LIU, J., SONG, D., ZHAO, Y., GUAN, S., MAIMAITILI, A., WANG, Y., FENG, W., WANG, Y., WAN, J., MAO, G., SHI, H., <(>&<)> YANG, X. (2020). PIPELINE EMBOLIZATION DEVICE FOR INTRACRANIAL ANEURYSMS IN A LARGE CHINESE COHORT: FACTORS RELATED TO ANEURYSM OCCLUSION. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 13, 1756286420967828. HTTPS://DOI.ORG/10.1177/1756286420967828. MEDTRONIC REVIEW OF THE LITERATURE ARTICLE FOUND A MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF THE PIPELINE EMBOLIZATION DEVICE (PED) FOR TREATMENT OF INTRACRANIAL ANEURYSMS IN THE CHINESE POPULATION. 1171 PATIENTS WITH 1322 INTRACRANIAL ANEURYSMS TREATED IN 1319 PROCEDURES WERE INCLUDED IN THE STUDY. THE AVERAGE PATIENT AGE WAS 53.9 ± 11.4 YEARS AND THE MAJORITY OF PATIENT'S INCLUDED IN THE STUDY WERE FEMALE (69.4%). 685 ANEURYSMS WERE TREATED WITH PED ONLY AND 637 ANEURYSMS WERE TREATED WITH PED PLUS COILING. 17 PATIENTS WERE NOTED TO HAVE DIED POST-OPERATIVELY. CAUSE OF DEATH WAS NOT NOTED IN THE ARTICLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1451067 PIPELINE INTRACRANIAL ANEURYSM FLOW DIVERTER OUT MICRO THERAPEUTICS, INC. DBA EV3 NV UNK PIPELINE UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 53 YR Female Death